News | Orthopedic Imaging | May 23, 2017

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

Data indicate disease-modifying aspects of AST-OPC1 may carry long-term benefits related to both recovery and maintenance of motor and sensory function

Asterias MRI Data Shows AST-OPC1 Cells Prevent Cavitation in Severe Spinal Cord Injury Patients

May 23, 2017 — Asterias Biotherapeutics Inc. recently announced new positive serial magnetic resonance imaging (MRI) data from its ongoing AST-OPC1 SCiStar Phase 1/2a clinical trial in patients with severe spinal cord injury.

Study data indicated that:

  • For the five AIS-A patients in the SCiStar study treated with 10 million AST-OPC1 cells (Cohort 2) who also received a serial MRI scan at six months of follow-up, the serial MRI scans indicated no sign of lesion cavities in any patient. These fluid-filled cavities typically form by about three months following severe spinal cord injury and prevent significant recovery of motor and sensory function;
  • For the three patients in Cohort 2 that have also completed 12 months of follow-up, serial MRI scans at 12 months continued to indicate no signs of lesion cavities; and
  • All three AIS-A patients who received a low dose of 2 million cells (Cohort 1) in the SCiStar study also showed no sign of lesion cavities in any patient through 1 year of follow-up.  All three patients are continuing long-term follow-up and will receive additional MRI scans annually.

The MRI results are supportive of the extensive pre-clinical data on AST-OPC1 showing that the cells durably engraft and help prevent cavitation at the injury site. Cavitation is a destructive process that occurs within the spinal cord following spinal cord injuries, and typically results in permanent loss of motor and sensory function. Additionally, a patient with cavitation can develop a condition known as syringomyelia, which results in additional neurological and functional damage to the patient.

Under the study protocol, patients are monitored by MRI scans at regular intervals over 12 months in order to assess status of the injection site and surrounding tissues.

For more information: www.asteriasbiotherapeutics.com

Related Content

News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
150-Year-Old Drug Might Improve Radiation Therapy for Cancer
News | Radiation Therapy | November 02, 2018
November 2, 2018 — A drug first identified 150 years ago and used as a smooth-muscle relaxant might make tumors more
SBRT Considered Safe Treatment Option for Patients With Multiple Metastases
News | Stereotactic Body Radiation Therapy (SBRT) | November 01, 2018
The NRG Oncology clinical trial BR001 tested the hypothesis that stereotactic body radiotherapy (SBRT) could be used...
Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...